What's new

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Mar 17, 2025 - 16:54
 0
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Read More

Tags:

Previous Article

Orca Bio to seek approval of T cell transplant after positive trial data

Next Article

Quest Nutrition debuts high-protein shake

Related Posts

Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025  0

Human medicines European public assessment report (EPAR): Remsima, infliximab, Date of authorisation: 10/09/2013, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 5, 2025  0

Human medicines European public assessment report (EPAR): Spherox, spheroids of human autologous matrix-associated chondrocytes, Date of authorisation: 10/07/2017, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025  0